NAD+ Side Effects: What the Human Evidence Shows

Human evidence on NAD+ safety is still developing, and direct NAD+ findings must be separated from studies of its precursors, nicotinamide riboside and NMN.

Trial readout8 min read

Key takeaway

NAD+ is a coenzyme involved in cellular energy metabolism and redox reactions. It is not a peptide. Direct human evidence now includes a randomized cardiac study that reported one minor dizziness event in the NAD+ group, a small pilot with no observed adverse events, and a clinic chart review describing transient symptoms in all six NAD+ recipients. Research on NR and NMN offers context about NAD+ biology, but it is not direct NAD+ safety evidence.

At a glance

Article typeTrial readout
Main guideNAD+: complete guide
Regulatory statusNot FDA-approved“Regulatory: NAD+ itself has no FDA approval” (NAD+: complete guide)
ClassCell metabolism & aging
Body systemsEndocrine & metabolism
Studies cited6 in this article · 32 across 7 articles on NAD+
ProductNAD+ product page

NAD+ side effects depend on the product and study being discussed. Small studies of direct NAD+ exposure have reported different experiences, while larger bodies of research often examine precursors such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), not NAD+ itself. FDA has also warned about adverse reactions associated with certain compounded sterile NAD+ preparations.

Quick answer: Reported NAD+ side effects in direct human observations include a single report of minor dizziness in a randomized cardiac trial and gastrointestinal discomfort, nausea, vomiting, increased heart rate, throat symptoms and chest pressure during a small clinic-based chart review. FDA has separately received reports of severe chills, shaking, vomiting and fatigue after exposure to certain compounded sterile NAD+ preparations, with concerns about endotoxin contamination. Evidence from NR or NMN studies should not be presented as if those participants received NAD+ itself.

What is NAD+, and is it a peptide?

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in cells. It participates in oxidation-reduction reactions and supports enzymes involved in energy metabolism, DNA repair and cellular signaling. NAD+ is not a peptide or protein. It is a dinucleotide made from two nucleotide units, and it has a central role in basic cell biology.

NAD+ has attracted attention in aging and metabolic research because cellular NAD+ levels and related pathways change in some experimental models and human conditions. That scientific interest has led to studies of direct NAD+ exposure and of compounds that cells can use to make NAD+, including NR and NMN. These are related but distinct interventions. A study of an NAD+ precursor is not a direct study of NAD+ itself.

The distinction matters for side-effect reporting. The compound administered, the formulation, the study population and the observation period all influence what can be concluded. This article therefore separates direct NAD+ reports from research on precursors.

What NAD+ side effects have been reported with direct exposure?

Direct human studies remain limited, but a randomized trial in a defined cardiac population now adds an important human safety dataset. Yu and colleagues published a single-center, randomized, placebo-controlled study of 180 adults with heart failure due to ischemic cardiomyopathy. The trial reported one case of minor dizziness in the NAD+ group, which subsided after about an hour; investigators discontinued the study product as a precaution. One participant in the placebo group reported chest discomfort. The paper reported no notable adverse effects on laboratory markers of liver, kidney function or glucose. These findings are encouraging within that specific hospital population, but do not establish general tolerability across other products or settings.

An earlier pilot by Grant and colleagues included eight healthy men in the NAD+ group and three controls. No adverse events were observed during the short monitored period. The sample cannot rule out uncommon or delayed effects.

A 2026 chart review by Reyna and colleagues examined six NAD+ recipients and eight NR recipients. Its abstract described moderate or severe gastrointestinal symptoms, increased heart rate and chest pressure during NAD+ sessions. The full text is internally inconsistent: one results subsection says no adverse events were documented, while the following summary reports symptoms in all six NAD+ recipients. Those symptoms were reported to resolve after the session. The study is retrospective and very small, so it cannot provide a reliable event rate. Its NR group is a separate comparator, not direct NAD+ exposure.

Table 1

What NAD+ side effects have been reported with direct exposure

Direct NAD+ evidenceStudy populationReported safety observationMain limitation
Yu et al., 2025/2026180 adults with ischemic cardiomyopathy and heart failure; randomized, placebo-controlled trialOne minor dizziness report in the NAD+ group; one chest-discomfort report in placebo; no notable lab safety changes reportedSingle-center study in a defined cardiac population; does not establish general or long-term tolerability
Grant et al., 201911 healthy men: 8 in the NAD+ group and 3 controlsNo adverse events observed during the six-hour study periodVery small pilot and short observation window
Reyna et al., 2026Clinic chart review: 6 NAD+ recipients and 8 NR recipientsAll six NAD+ recipients had symptoms including gastrointestinal discomfort, nausea, vomiting, increased heart rate and chest or throat symptoms during the sessionRetrospective, very small, non-randomized study
FDA safety communicationReports involving certain compounded sterile NAD+ preparationsSevere chills, shaking, vomiting and fatigue were reported after exposureSpontaneous reports do not establish incidence or prove every product has the same risk

What has FDA warned about?

FDA has reminded compounders to use ingredients suitable for sterile compounding. The agency described reports of severe chills, shaking, vomiting and fatigue after people received compounded NAD+ products. FDA stated that some symptoms were consistent with excessive endotoxin exposure. The agency also explained that food-grade ingredients may not be suitable for sterile drug preparation without appropriate processing and controls.

This warning concerns product quality and contamination risks in certain compounded preparations. It should not be rewritten as proof that the NAD+ molecule itself causes every reported symptom. Nor should it be used to generalize the same risk to every preparation. The agency's central point is that the suitability and quality of ingredients for sterile compounding matter.

Spontaneous reports can identify potential problems, but they do not provide a denominator or establish event frequency. They also cannot prove causation. A safety review must distinguish a report from a confirmed causal relationship.

What do NR and NMN studies say about side effects?

NR and NMN are precursors in NAD+ biosynthesis, not NAD+ itself. Their clinical findings help explain the pathway but cannot establish direct NAD+ tolerability. A randomized trial by Conze and colleagues found NR generally well tolerated in healthy overweight adults. A separate short randomized study by Fukamizu and colleagues found no severe adverse events with NMN in healthy adults. These results apply to those precursors and study populations, not to direct NAD+ preparations.

A 2026 systematic review by Gallagher and Emmanuel assessed 113 studies of NAD-related interventions, including 33 human intervention studies and 80 rodent studies. Human evidence largely concerned oral NR and NMN, with heterogeneous outcomes. The review found no eligible outcome trials of direct NAD+ for anti-aging or wellness indications. A separate 2026 narrative review by Alangari and colleagues focused on wellness and translational use. It described that literature as low quality, mainly small uncontrolled studies, observational reports and case reports with limited follow-up. Its scope differs from the disease-specific cardiac trial by Yu and colleagues. The review also disclosed that one author was employed by a wellness company, a factor readers can consider when weighing its interpretation.

The research signal is that the NAD+ pathway remains biologically important and supports several active lines of investigation. The key scientific question is which intervention changes which biomarkers, in which population, and whether those changes affect meaningful outcomes. NAD+, NR and NMN should not be treated as interchangeable.

Why is the NAD+ safety picture still incomplete?

The direct NAD+ studies differ in design and population. A randomized study in 180 adults with ischemic cardiomyopathy reported one minor dizziness event, while an early pilot observed no adverse events over a short period. A later chart review described symptoms in all six NAD+ recipients. These findings should not be combined into a single risk percentage because the populations, products and methods of collecting events differed.

Product quality also matters. FDA focused on ingredient suitability for sterile compounding and reports consistent with excessive endotoxin exposure. A formulation-specific quality problem is not proof of a pharmacological adverse effect from NAD+ itself.

Long-term outcomes remain under study. Future research needs prospective designs, clear adverse-event reporting and well-characterized preparations. It should analyze NAD+, NR and NMN separately.

For more background, see Vitrapep's NAD+ complete guide, NAD+ and sirtuin mechanism article, and NAD+ research price page.

Vitrapep research material

Vitrapep sells NAD+ for laboratory research use only. It is not for human or veterinary use.

NAD+ 500 mg research vial

NAD+

Lyophilized Research use only

Specifications for the NAD+ sold for laboratory research. COA available with each lot.

View NAD+ specifications

Frequently asked questions

Is NAD+ a peptide?

No. NAD+ is a dinucleotide coenzyme involved in cellular energy metabolism and redox reactions. It is included here because it is part of the Vitrapep research catalogue, not because it is a peptide.

What side effects have been reported with NAD+?

A small 2026 chart review described gastrointestinal symptoms, increased heart rate and throat or chest symptoms during NAD+ sessions. FDA separately described severe chills, shaking, vomiting and fatigue associated with certain compounded sterile NAD+ preparations.

Are NR and NMN the same as NAD+?

No. NR and NMN are precursors that cells can use to produce NAD+. Their clinical safety findings should not be treated as direct NAD+ safety findings.

Did a human NAD+ study report no side effects?

A small 2019 pilot involving eight NAD+ participants reported no adverse events during its short observation period. Its size and duration cannot establish broad or long-term safety.

What did FDA warn about in compounded NAD+ preparations?

FDA described reports of severe chills, shaking, vomiting and fatigue and raised concern about excessive endotoxin exposure in certain compounded sterile preparations. The warning emphasizes ingredient suitability and preparation quality.

What to know now

  • NAD+ is a coenzyme, not a peptide, and direct NAD+ evidence is much smaller than the broader NR and NMN precursor literature.
  • Small direct human studies have reported both no observed events in one pilot and multiple transient symptoms in a later clinic chart review.
  • FDA has warned about adverse reactions associated with certain compounded sterile NAD+ preparations and concerns consistent with endotoxin exposure.

What we’re watching

  • Larger prospective studies that evaluate direct NAD+ exposure with clear adverse-event definitions and follow-up.
  • Further FDA communications about compounded sterile NAD+ preparations and ingredient suitability.
  • Systematic reviews that separate direct NAD+ studies from NR and NMN precursor trials.

Also in the library

More for endocrine & metabolism

All 41 compounds for endocrine & metabolism

Sources: Grant 2019, Frontiers in Aging Neuroscience, 11; Reyna 2026, Frontiers in Aging, 7; Yu 2025, American Journal of Cardiovascular Drugs, 26; U.S. Food and Drug Administration 2026; Gallagher 2026, Ageing Research Reviews, 116; Conze 2019, Scientific Reports, 9; Fukamizu 2022, Scientific Reports, 12; Alangari 2026, Frontiers in Aging, 7. All 8 citations

Back to the research library

References

  1. Grant, R., et al. (2019). A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a six-hour infusion of NAD+. Frontiers in Aging Neuroscience, 11, 257. https://pubmed.ncbi.nlm.nih.gov/31572171/
  2. Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, 1652582. https://pubmed.ncbi.nlm.nih.gov/41704678/
  3. Yu, X., et al. (2025, issue date 2026). Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: A randomized, placebo-controlled trial. American Journal of Cardiovascular Drugs, 26(1), 97-106. https://pmc.ncbi.nlm.nih.gov/articles/PMC12779688/
  4. U.S. Food and Drug Administration. (2026). FDA reminds compounders to use ingredients suitable for sterile compounding. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-use-ingredients-suitable-sterile-compounding
  5. Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://pubmed.ncbi.nlm.nih.gov/41655607/
  6. Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. https://pubmed.ncbi.nlm.nih.gov/31278280/
  7. Fukamizu, Y., et al. (2022). Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. Scientific Reports, 12, 14442. https://pubmed.ncbi.nlm.nih.gov/36002548/
  8. Alangari, A., Arif, J., Al Qureshah, F., & Alkhodairy, F. (2026). Narrative review of intravenous NAD+ and NAD+ precursors in wellness and translational medicine. Frontiers in Aging, 7. https://doi.org/10.3389/fragi.2026.1887175